Christopher Peetz is the CEO of Mirum Pharmaceuticals, Inc., a role he has held since 2019. Under his leadership, the company focused on developing treatments for liver diseases, including two major products: Livmarli and maralixibat. His experience in pharmaceuticals is...

Christopher Peetz is the CEO of Mirum Pharmaceuticals, Inc., a role he has held since 2019. Under his leadership, the company focused on developing treatments for liver diseases, including two major products: Livmarli and maralixibat. His experience in pharmaceuticals is backed by a strong performance record at Mirum, where he saw the company achieve significant clinical milestones, particularly in drug approvals. In 2023, Peetz earned a total compensation of $1,303,200, mostly through salary and performance-based bonuses recognizing his success in meeting corporate goals. Notably, he received an annual performance bonus for achieving 160% of corporate targets.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Mirum Pharmaceuticals, Inc. CEOs

M

Christopher Peetz

Founder and CEO of Mirum Pharmaceuticals, Inc.

Education

MBA from Stanford Graduate School of Business

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1979 - 46 years ago

CEO of Mirum Pharmaceuticals, Inc. for

6 years 2 months (Mar 2019 - Present)

Previous Experience

Chief Executive Officer of Flashlight Therapeutics, Inc.

Rivals

Competitors/colleagues of Christopher Peetz

Holdings

See how much did Christopher Peetz make over time.

Christopher Peetz has significant holdings in Mirum Pharmaceuticals. As of the last report, he owns 68,027 shares directly and has quite a bit tied up in options, totaling approximately 820,937 options exercised within the next 60 days. His wealth in...

Christopher Peetz has significant holdings in Mirum Pharmaceuticals. As of the last report, he owns 68,027 shares directly and has quite a bit tied up in options, totaling approximately 820,937 options exercised within the next 60 days. His wealth in these holdings can fluctuate, especially during pivotal moments in the company's stock performance. Peetz's highest holdings were during earlier fruitful years for the stock, but his influence continues to resonate as the company progresses. His family trust further holds 201,570 shares, adding to his strong position in the company.

Total Stock Sold

$3.55M

MIRM

$3.55M

88,979 MIRM shares

What if they kept their stock?

If Christopher Peetz didn't sell their stock, today they would have:
Extra MIRM88,979 shares worth $1.55M.
This is -56.49% and $2.01M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Christopher Peetz.

MIRM

$1.88M

MIRM at $46.90/share

Mar 3, 2025

Sale

MIRM

$438.92K

MIRM at $48.22/share

Feb 3, 2025

Sale

MIRM

$327.66K

MIRM at $47.92/share

Jan 23, 2025

Sale

MIRM

$320.64K

MIRM at $42.82/share

Jan 7, 2025

Sale

MIRM

$1.37K

MIRM at $21.05/share

Nov 8, 2024

Received

MIRM

$17.19K

MIRM at $21.05/share

May 10, 2024

Received

MIRM

$157.49K

MIRM at $26.19/share

Feb 2, 2024

Sale

MIRM

$146.03K

MIRM at $28.03/share

Jan 8, 2024

Sale

MIRM

$141.01K

MIRM at $25.65/share

Jul 3, 2023

Sale

MIRM

$21.26K

MIRM at $16.92/share

May 10, 2023

Received

Compensation History

See how much did Christopher Peetz make over time.

Christopher Peetz's compensation reflects his performance-oriented approach. In 2023, he earned a total of $1,303,200, which included a salary of $660,000, a bonus of $633,600 based on impressive corporate performance, and additional contributions to his 401(k). This aligns with Mirum's strategy of tying executive pay closely to success against corporate objectives. Over his tenure, Peetz has consistently seen his salary and bonuses grow, illustrating both his leadership impact and the company's increasing achievements across key metrics. His compensation structure puts significant emphasis on achieving corporate goals, ensuring that he is rewarded for the company's success.

Year

2023

Total Compensation

$1.31M

Salary

$660.00K

Board Justification

The compensation philosophy aims to align executive compensation with company performance and market benchmarks to attract and retain top talent.

Bonus

$633.60K

Board Justification

Annual performance-based bonuses awarded in January 2024 in recognition of 2023 performance, based on corporate goals achievement at 160%.

Other

$13.20K

Board Justification

Matching payments under the 401(k) Plan, a qualified deferred compensation plan.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock vested in 2023 as the focus is on cash compensation and bonuses.

Performance Metrics

Performance metrics for 2023 included product revenue, commercial expansion, product candidate development, and operational goals.

Other Mirum Pharmaceuticals, Inc. CEOs

Here are other CEOs of Mirum Pharmaceuticals, Inc.

Michael Grey

Founder and Ex-CEO of Mirum Pharmaceuticals, Inc.

May 2018 - March 2019